EmailThe Healthcare sector +2.3% is in line with the S&P 500 +2.4%.
News: KIPS +5% reports FDA has indicated it has provided the Co's IDE information to these outside experts for this review only within the past week, COV +7.8% announces $2 billion buyback, NEOP +6% submits new drug application for Lymphoseek, AGEN +12% priced a ~13.72 million share common stock offering at $0.51/share, CCM +5.4% and GE Healthcare, unit of (GE) sign MOU for preferred partnership in China, ABC +5.1% authorizes a new $750 mln share repurchase program, MYL +4.1% CEO buys 10K shares at 17.46, AMLN +4.1% Bydureon FDA action date set for January 28, 2012, GNVC +2.8% renews stockholder rights plan, GILD +2.3% announced that the FDA has approved Complera, and resolves U.S. Food and Drug Administration warning letter related to San Dimas manufacturing facility, NVO +1.8% discloses agreement to purchase 5.1 mln B shares from Novo A/S, KCI +1.8% rumor related to potential higher bid, MDGN +1% awarded grant from the Israeli office of the chief scientist, AFFY -0.5% announces assignment of March 27, 2012 PDUFA date for peginesatide new drug application, SCLN -3.6% files for 8.3 mln share common stock offering by selling shareholders, SHP -3.3% announced accelerated achievement of milestones for two multi-stage projects, VSCI -6.4% following earnings, and OXGN -9.7% following earnings.
Broker Research: INHX +6.2% upgraded at Noble, BTX +3.6% initiated at WBB Securities, THRX +3.5% initiated at BofA/Merrill, COO +4.1% initiated at William Blair.
